Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2013-02-08 Regulatory Filings
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Pergamum AB announces a strategic collaboration with Cadila Pharmaceuticals Ltd
Regulatory Filings Classification · 1% confidence The document is a press release announcing a strategic collaboration between two pharmaceutical companies, Pergamum AB and Cadila Pharmaceuticals Ltd, regarding the development of a novel therapeutic peptide. This type of announcement, detailing a business agreement, partnership, or strategic move that is not a standard financial report (like 10-K, ER, or IR), typically falls under general corporate news or regulatory filings. Since the content is a specific business development announcement and not a standard financial disclosure, it does not fit well into the defined financial report categories (10-K, IR, ER, etc.). It is not a management change (MANG), director dealing (DIRS), dividend notice (DIV), or capital change (CAP). Given the options, the most appropriate classification for a significant, non-standard corporate announcement that doesn't fit elsewhere is the general regulatory/miscellaneous category, RNS, or potentially a category related to M&A/Partnerships if one existed. Since 'M&A Activity (TAR)' is defined for merger proposals or takeover bids, and this is a collaboration/partnership, RNS (Regulatory Filings - general fallback) is the best fit for this type of press release announcing a strategic business development.
2013-02-08 English
Karolinska Development startar samarbete med Mayo Clinic
Regulatory Filings Classification · 1% confidence The document is a press release dated February 4, 2013, announcing a collaboration agreement between Karolinska Development AB and Mayo Clinic to identify life science investment opportunities. This is a corporate announcement regarding a strategic partnership, not a mandatory periodic financial filing (like 10-K or IR) or a specific transaction like a merger (TAR) or share repurchase (POS). It details a business development activity. Since there is no specific category for 'Strategic Partnership Announcement' or 'Business Development News', and it is not a standard regulatory filing like an earnings release (ER) or a management discussion (MDA), the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as a general category for miscellaneous regulatory announcements that don't fit elsewhere, although this is primarily a press release. Given the options, RNS is the best fit for a general, non-financial-reporting corporate news item.
2013-02-04 Swedish
Karolinska Development signs agreement with Mayo Clinic
Regulatory Filings Classification · 1% confidence The document announces a strategic agreement between Karolinska Development and Mayo Clinic to identify commercialization opportunities for life science innovations. This is a specific corporate action announcement related to business development and potential future investments/partnerships, rather than a standard periodic financial report (10-K, IR, ER) or a shareholder vote material (AGM-R, DEF 14A). It details a collaboration aimed at developing and commercializing innovations. Since there is no specific category for 'Strategic Partnership Announcement' or 'Business Development Update', and the content is a material announcement that affects the company's operational strategy and potential deal flow, it fits best under the general 'Regulatory Filings' (RNS) category as a significant, non-standard corporate announcement, or potentially 'Capital/Financing Update' (CAP) if the collaboration implies future joint funding, but 'RNS' is the most appropriate fallback for material news that isn't explicitly financial reporting or governance. Given the nature of the announcement (a major collaboration agreement), RNS is the most suitable general regulatory disclosure category.
2013-02-04 English
Dilaforette – Phase II study with sevuparin for the treatment of severe malaria initiated
Regulatory Filings Classification · 1% confidence The document is a press release announcing that Dilaforette has received regulatory approval in India to initiate a Phase II clinical study for sevuparin in severe malaria patients. It details the study objectives, collaborators (MORU, FDA discussions), and provides quotes from management. This type of announcement, detailing clinical trial progress and regulatory milestones, is typically classified as a general corporate update or news release. Since there is no specific category for 'Clinical Trial Initiation' or 'Press Release', and it is not a formal financial report (10-K, IR, ER), nor a management/board change (MANG), nor a director's dealing (DIRS), nor a financing event (CAP), the most appropriate fallback category is 'Regulatory Filings' (RNS), as it is a formal announcement of a regulatory/clinical development step, often disseminated via regulatory news services.
2013-01-30 English
Dilaforette – Fas II-studie med sevuparin för behandling av svår malaria inledd
Regulatory Filings Classification · 1% confidence The document is a press release dated January 30, 2013, announcing that Dilaforette has received approval to start a Phase II study for sevuparin in India for severe malaria. It details the study plan, quotes management and investigators, and provides background information on the disease and the companies involved (Dilaforette, MORU, Karolinska Development). This type of announcement, focusing on clinical trial progress and regulatory milestones, is typically classified as a general corporate announcement or news release. Since it is not a formal financial report (like 10-K or IR), a specific earnings release (ER), or a management discussion (MDA), it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for significant corporate news that doesn't fit other specific financial reporting codes. The document length (4833 chars) is substantial enough to be the primary announcement, not just a brief notice of publication (RPA).
2013-01-30 Swedish
Pergamum reports positive Phase II data from clinical trial in outer ear infections
Earnings Release Classification · 1% confidence The document is a press release dated December 21, 2012, announcing positive Phase II clinical trial data for a drug candidate (DPK-060) for treating outer ear infections. It details trial endpoints, safety, efficacy results, and future plans (searching for a corporate partner). This content is characteristic of an Earnings Release (ER) or a general corporate update, but since it focuses purely on clinical trial results and business development rather than comprehensive financial performance for a reporting period, it fits best under the general category of corporate news that is not a formal financial report (like 10-K or IR). Given the options, it is a specific announcement of operational/clinical progress. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal Financial Report (10-K/IR). It is most closely aligned with an Earnings Release (ER) which often includes operational highlights, or potentially Regulatory Filings (RNS) if it were a mandatory disclosure, but ER is often used for key operational news releases. Since it is a positive clinical trial update, which drives investor interest, ER is the most appropriate fit among the provided choices for a major operational announcement. FY 2012
2012-12-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.